Meeting
2013 ASCO Annual Meeting
PIK3CA mutations in primary HER2-positive and triple negative breast cancer.
Authors
Sibylle Loibl
German Breast Group, Neu-Isenburg, Germany
Sibylle Loibl , Carsten Denkert , Sherene Loi , Fabrice Andre , Berit Mueller , Andreas Schneeweiss , Jens U. Blohmer , Christian Jackisch , Guo Sanxing , Stephan Gade , Peter A. Fasching , Christian Schem , Christos Sotiriou , Michael Untch , Gunter Von Minckwitz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Genomic and Epigenomic Biomarkers
Clinical Trial Registration Number
NCT01426880
Citation
J Clin Oncol 31, 2013 (suppl; abstr 11061)
DOI
10.1200/jco.2013.31.15_suppl.11061
Abstract #
11061
Poster Bd #
45H
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Impact of somatic PIK3CA and ERBB family mutations on pathological complete reponse (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
First Author: Sinead Toomey
Poster
2015 ASCO Annual Meeting
A randomized phase III trial comparing two dose-dense, dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto).
First Author: Andreas Schneeweiss
Poster
2023 ASCO Annual Meeting
Association of HER2/CEP17 ratio with pCR after HER2-directed neoadjuvant treatments in the phase III NeoALTTO trial.
First Author: Christian F. Singer
Poster
2019 ASCO Annual Meeting
Correlation between mutation landscape and clinical outcomes of neoadjuvant therapy in HER2-positive breast cancer patients.
First Author: Ning Liao